PDF herunterladen
J Neurol Surg B Skull Base 2022; 83(S 02): e49-e53
DOI: 10.1055/s-0040-1722665
Original Article

Changes in the Options for Management of Prolactin Secreting Pituitary Adenomas

Sherry L. Iuliano
1   Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
,
Wenya Linda Bi 
1   Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
,
Edward R. Laws Jr
1   Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
› Institutsangaben Funding None.
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Objectives Initial therapy for the management of prolactinomas has long been maintained to be medical, consisting of a dopamine agonist. These therapies may have troublesome side effects, and some prolactinomas are resistant to medical therapy regarding lowering prolactin levels or shrinking the tumor. These issues have revived interest in surgery for prolactin-secreting adenomas as an early therapeutic option. We report our analysis of surgery for prolactin microadenomas in women, using the transsphenoidal endoscopic approach.

Design We reviewed a contemporary series of 33 women (mean age = 31.8 years) with microprolactinomas who underwent early surgical intervention, which was a three-dimensional transnasal transsphenoidal endoscopic operation.

Setting The study was conducted at a tertiary academic referral center for pituitary tumors.

Main Outcome Measures Preoperative and postoperative prolactin.

Results Overall, 28 patients had received preoperative dopamine agonists, 24 of these experienced a variety of drug-related side effects, and 4 had tumors that were resistant to lowering prolactin or tumor shrinkage. Preoperative prolactin levels averaged 90.3 ng/mL (range = 30.7–175.8 ng/mL). We observed a 94% normalization rate in postoperative prolactin (mean = 10.08 ng/mL, range = 0.3–63.1 ng/mL). During the follow-up (mean = 33.9 months), five patients had elevated prolactin; four required reinitiation of medical therapy, two had surgical reexploration, and none received radiation therapy. Complications included syndrome of inappropriate antidiuretic hormone secretion (n = 3), transient diabetes insipidus (n = 1), postoperative epistaxis (n = 1), and fat graft site infection (n = 1).

Conclusion This review supports the consideration of transsphenoidal surgery as an early intervention for some women with prolactin-secreting microadenoma. Indications include significant side effects of medical therapy and tumors that do not respond to standard medical management.

Keywords

prolactinoma - pituitary tumor - dopamine agonist side effects - endoscopic transsphenoidal surgery

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors. This study was approved by the institutional review board of the Brigham and Women's Hospital.




Publikationsverlauf

Eingereicht: 26. Juli 2020

Angenommen: 01. November 2020

Artikel online veröffentlicht:
18. Februar 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Forbes AP, Henneman PH, Griswold GC, Albright F. Syndrome characterized by galactorrhea, amenorrhea and low urinary FSH: comparison with acromegaly and normal lactation. J Clin Endocrinol Metab 1954; 14 (03) 265-271
    CrossrefPubMedGoogle Scholar
  • 2 Jane Jr JA, Laws Jr ER. The surgical management of pituitary adenomas in a series of 3,093 patients. J Am Coll Surg 2001; 193 (06) 651-659
    PubMedGoogle Scholar
  • 3 Coulam CB, Annegers JF, Abboud CF, Laws Jr ER, Kurland LT. Pituitary adenoma and oral contraceptives: a case-control study. Fertil Steril 1979; 31 (01) 25-28
    CrossrefPubMedGoogle Scholar
  • 4 Hardy J. Microsurgery of hypersecreting pituitary microadenomas. Ann Endocrinol (Paris) 1971; •••: 195-196
    PubMedGoogle Scholar
  • 5 Hardy J. Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 1969; 16: 185-217
    CrossrefPubMedGoogle Scholar
  • 6 Hardy J. Transsphenoidal surgery of hypersecreting pituitary tumors. In: Kohler POR. G.T., ed. Diagnosis and Treatment of Pituitary Tumors. New York: Elsevier; 1973: 179-194
    Google Scholar
  • 7 Hardy J. Transsphenoidal microsurgery of prolactinomas: report on 355 cases. In: Tolis G. ed. Prolactin and Prolactinomas. New York: Raven Press; 1983: 431-440
    Google Scholar
  • 8 Vance ML, Thorner MO. Prolactinomas. Endocrinol Metab Clin North Am 1987; 16 (03) 731-753
    CrossrefPubMedGoogle Scholar
  • 9 Thorner MO, McNeilly AS, Hagan C, Besser GM. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. BMJ 1974; 2 (5916): 419-422
    CrossrefPubMedGoogle Scholar
  • 10 Besser GM, Thorner MO. Bromocriptine in the treatment of the hyperprolactinaemia-hypogonadism syndromes. Postgrad Med J 1976; 52 (52, Suppl 1): 64-70
    PubMedGoogle Scholar
  • 11 Biller BM, Molitch ME, Vance ML. et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81 (06) 2338-2343
    PubMedGoogle Scholar
  • 12 Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 349 (21) 2023-2033
    CrossrefPubMedGoogle Scholar
  • 13 Casanueva FF, Molitch ME, Schlechte JA. et al. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65 (02) 265-273
    CrossrefPubMedGoogle Scholar
  • 14 Melmed S, Casanueva FF, Hoffman AR. et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96 (02) 273-288
    CrossrefPubMedGoogle Scholar
  • 15 Biswas M, Smith J, Jadon D. et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 2005; 63 (01) 26-31
    CrossrefPubMedGoogle Scholar
  • 16 Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf) 2014; 80 (06) 863-868
    CrossrefPubMedGoogle Scholar
  • 17 Celik E, Ozkaya HM, Poyraz BC, Saglam T, Kadioglu P. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine 2018; 62 (03) 692-700
    CrossrefPubMedGoogle Scholar
  • 18 Dogansen SC, Cikrikcili U, Oruk G. et al. Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab 2019; 104 (07) 2527-2534
    CrossrefPubMedGoogle Scholar
  • 19 Di Sarno A, Landi ML, Cappabianca P. et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001; 86 (11) 5256-5261
    CrossrefPubMedGoogle Scholar
  • 20 Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. J Neurosurg 2011; 114 (05) 1369-1379
    CrossrefPubMedGoogle Scholar
  • 21 Molitch ME. Management of medically refractory prolactinoma. J Neurooncol 2014; 117 (03) 421-428
    CrossrefPubMedGoogle Scholar
  • 22 Jane Jr JA, Thapar K, Kaptain GJ, Maartens N, Laws Jr ER. Pituitary surgery: transsphenoidal approach. Neurosurgery 2002; 51 (02) 435-442 , discussion 442–444
    CrossrefPubMedGoogle Scholar
  • 23 Massoud F, Serri O, Hardy J, Somma M, Beauregard H. Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surg Neurol 1996; 45 (04) 341-346
    CrossrefPubMedGoogle Scholar
  • 24 Turner HE, Adams CB, Wass JA. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?. Eur J Endocrinol 1999; 140 (01) 43-47
    CrossrefPubMedGoogle Scholar
  • 25 Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 2011; 14 (03) 222-230
    CrossrefPubMedGoogle Scholar
  • 26 Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 2012; 166 (05) 779-786
    CrossrefPubMedGoogle Scholar
  • 27 Tamasauskas A, Sinkunas K, Bunevicius A, Radziunas A, Skiriute D, Deltuva VP. Transsphenoidal surgery for microprolactinomas in women: results and prognosis. Acta Neurochir (Wien) 2012; 154 (10) 1889-1893
    CrossrefPubMedGoogle Scholar
  • 28 Rutkowski MJ, Aghi MK. Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes. Expert Rev Endocrinol Metab 2018; 13 (01) 25-33
    CrossrefPubMedGoogle Scholar
  • 29 Donoho DA, Laws Jr ER. The role of surgery in the management of prolactinomas. Neurosurg Clin N Am 2019; 30 (04) 509-514
    CrossrefPubMedGoogle Scholar
  • 30 Micko A, Vila G, Höftberger R, Knosp E, Wolfsberger S. Endoscopic transsphenoidal surgery of microprolactinomas: a reappraisal of cure rate based on radiological criteria. Neurosurgery 2019; 85 (04) 508-515
    CrossrefPubMedGoogle Scholar
  • 31 Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S. Surgery for prolactinomas: a better choice?. Pituitary 2020; 23 (01) 45-51
    CrossrefPubMedGoogle Scholar
  • 32 Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F. et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. a systematic review and meta-analysis. J Clin Endocrinol Metab 2020; 105 (03) dgz144
    CrossrefPubMedGoogle Scholar
  • 33 Hamilton DK, Vance ML, Boulos PT, Laws ER. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005; 8 (01) 53-60
    CrossrefPubMedGoogle Scholar